Two different approaches to attack the opioid-fueled substance use disorder crisis are on display this week, as Congress readies itself for action on more legislation, while 2 major medical organizations focused on payment models in order to deliver improved care.
Two different approaches to attack the opioid-fueled substance use disorder (SUD) crisis are on display this week, as Congress readies itself for action on more legislation, while 2 major medical organizations focused on payment models in order to deliver improved care.
Senator Lamar Alexander, R-Tennessee, and Senator Patty Murray, D-Washington, introduced bipartisan opioid legislation Tuesday and said the Senate Health Committee will consider the legislation next week.
Alexander’s office said the bill is composed of 40 different proposals, mostly from Republican and Democratic members of the Senate health committee, and is the result of 7 hearings over several months. Alexander is the chair of the health committee and Murray is the ranking member.
The senators said the bill, called the Opioid Crisis Response Act of 2018 (S. 2680), will improve the ability of HHS, the FDA, the CDC, the National Institutes of Health, as well as the departments of education, labor, the Health Resources and Service Administration, and the Substance Abuse and Mental Health Services Administration to address the crisis, which is estimated to kill about 100 people per day.
Among other measures, the bill will:
Also, this week, the House Energy and Commerce’s Health Subcommittee will hear from patient activists who lost family members to opioids. The subcommittee has also held hearings on close to 3 dozen bills about opioids.
Separately, the American Medical Association and the American Society of Addiction Medicine jointly announced a proposed alternative payment model to treat patients with SUD.
In a joint statement, the organizations said they hoped their model would spur conversations with insurers about how to pay for evidence-based care, such as a combination of medication assisted treatment and psychosocial support.
The new model, known as Patient-Centered Opioid Addiction Treatment (P-COAT), is aimed at increasing the number of patients who are able to successfully manage their condition while also reducing healthcare spending on costs such as emergency department visits and hospitalizations.
The payment model seeks to increase utilization of, and access to, medications for the treatment of opioid use disorder by providing the appropriate financial support to successfully treat patients and broaden the coordinated delivery of medical, psychological, and social support services. P-COAT is also designed to support office-based opioid treatment in order to facilitate coordination between multiple treatment providers.
Current payment systems are insufficient to identifiy, treat and diagnose SUD, and prior authorizations make it difficult to deliver care, the organizations said.
NAACOS Continues Pushing Forward on the Transition to Value-Based Care
September 21st 2020Allison Brennan, MPP, discusses legislation that would affect accountable care organizations (ACOs), the impact coronavirus disease 2019 had on ACOs, and the fall National Association of ACOs meeting.
Listen
Examining Physician-Initiated Alternative Payment Models, a New Wave of Payment Reform
September 12th 2019To date, most alternative payment models (APMs) that have emerged in the shift toward value-based care have been initiated by payers and focused on primary care providers. However, there has recently been a new wave of payment reform in which providers, mostly specialists, are designing and implementing their own APMs in their practices. A study published in the September issue of The American Journal of Managed Care® analyzed some of these new payment models to gain insight into what providers are prioritizing in their APMs.
Listen
Clinical Trials Won’t Cause Financial Harm for Practices in Medicare Payment Models, Study Finds
June 28th 2024Ishwaria Subbiah, MD, of SCRI Oncology Partners, discusses new findings presented at ASCO 2024. This interview will appear in the annual ASCO recap issue of Evidence-Based Oncology.
Read More